ID: ALA4591850

Max Phase: Preclinical

Molecular Formula: C21H26N4O5S

Molecular Weight: 446.53

Molecule Type: Unknown

Representations

Canonical SMILES:  CN(C)C1(C#CC#Cc2cc3n(c2)C(=O)N(CC[C@](C)(C(=O)NO)S(C)(=O)=O)C3)CC1

Standard InChI:  InChI=1S/C21H26N4O5S/c1-20(18(26)22-28,31(4,29)30)11-12-24-15-17-13-16(14-25(17)19(24)27)7-5-6-8-21(9-10-21)23(2)3/h13-14,28H,9-12,15H2,1-4H3,(H,22,26)/t20-/m1/s1

Standard InChI Key:  CABOMMUIXDDELT-HXUWFJFHSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 446.53

Molecular Weight (Monoisotopic): 446.1624

AlogP: 0.42

#Rotatable Bonds: 6

Polar Surface Area: 111.95

Molecular Species: NEUTRAL

HBA: 7

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 9

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 8.73

CX Basic pKa: 7.78

CX LogP: -0.52

CX LogD: -0.80

Aromatic Rings: 1

Heavy Atoms: 31

QED Weighted: 0.37

Np Likeness Score: -0.23

References

1. Panchaud P, Surivet JP, Diethelm S, Blumstein AC, Gauvin JC, Jacob L, Masse F, Mathieu G, Mirre A, Schmitt C, Enderlin-Paput M, Lange R, Gnerre C, Seeland S, Herrmann C, Locher HH, Seiler P, Ritz D, Rueedi G..  (2020)  Optimization of LpxC Inhibitor Lead Compounds Focusing on Efficacy and Formulation for High Dose Intravenous Administration.,  63  (1): [PMID:31804829] [10.1021/acs.jmedchem.9b01605]

Source

Source(1):

• Scientific Literature